Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:19 AM
Ignite Modification Date:
2025-12-25 @ 3:19 AM
NCT ID:
NCT02598505
Eligibility Criteria:
Inclusion Criteria:
* Male and female adults aged ≥ 18 years who have signed an Informed Consent Form.
* Patients with light chronic obstructive pulmonary disease never treated with bronchodilator drugs
* Co-operative patients
* Patients with a clinical diagnosis of chronic heart failure (HF)
* chronic myeloproliferative disorder with ejection fraction \< 40% with B Blockers therapy since at least 2 months. Optimized and individually tailored drug treatment including B blocker (Carvedilol or bisoprolol)
* Capability of performing Cardiopulmonary Exercise Test and lung diffusion test
Exclusion Criteria:
History or clinical documentation of:
* pulmonary embolism
* primary valvular heart disease
* pericardial disease
* severe obstructive lung disease
* significant peripheral vascular disease
* exercise-induced angina, st changes, or severe arrhythmias.
* Patients with diabetes Type I or uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range or HbA1c \> 8.0 % of total hemoglobin measured.
* Use of bronchodilators.
* Patients with a history (or family history) of long QT syndrome or whose corrected QT interval interval (Fridericia) measured at Visit 2 is prolonged: \>450 ms (males) or \>470 ms (females) as assessed by the central electrocardiogram (ECG) interpretation.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02598505
Study Brief:
Protocol Section:
NCT02598505